These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 2308977)
1. Lymphokine-activated killer (LAK) cell purging of bone marrow. Cramer DV; Long GS Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977 [TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms. Long GS; Cramer DV; Harnaha JB; Hiserodt JC Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956 [TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Long GS; Hiserodt JC; Harnaha JB; Cramer DV Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797 [TBL] [Abstract][Full Text] [Related]
4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
5. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. Teichmann JV; Ludwig WD; Thiel E Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400 [TBL] [Abstract][Full Text] [Related]
7. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327 [TBL] [Abstract][Full Text] [Related]
8. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis. Rolstad B; Benestad HB Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576 [TBL] [Abstract][Full Text] [Related]
9. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001 [TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL; Herberman RB; Hiserodt JC Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411 [TBL] [Abstract][Full Text] [Related]
11. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Klingemann HG; Wong E; Maki G Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301 [TBL] [Abstract][Full Text] [Related]
12. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related]
14. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related]
15. [Experimental study of LAK and activated NK cells affecting hematopoiesis in mice]. Sun K; Zhang M; Tian Z Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):405-8. PubMed ID: 11721419 [TBL] [Abstract][Full Text] [Related]
16. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease. Azuma E; Yamamoto H; Kaplan J J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409 [TBL] [Abstract][Full Text] [Related]
18. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Klingemann HG; Deal H; Reid D; Eaves CJ Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650 [TBL] [Abstract][Full Text] [Related]